Praxis Precision Medicines, Inc. PRAX
Set alert
At close · Oct 30
After hours · Oct 30, 4:33 PM ET
- YTD
- -2.99%
- 1 year
- +42.25%
- Open
- 283.92
- Prev close
- 288.62
- Mkt cap
- 7.98B
- Vol
- 306.56K
- Avg vol
- 461.47K
- EPS
- -12.95
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 280.00
- High
- 290.06
- Forward P/E
- -30.09
- Beta
- 2.81
- Short ratio
- 7.11
- Inst. own
- 123.49%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2026
- 50-d avg
- 302.86
- 200-d avg
- 314.90
- 1y target
- 650.00
News
5 days ago globenewswire.com
Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation
BOSTON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company,…
-
2 weeks ago benzinga.com
JP Morgan Initiates Coverage On Praxis Precision Medicine with Overweight Rating, Announces Price Target of $700
JP Morgan analyst Tessa Romero initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX) with a Overweight rating and announces Price Target of $700.
-
2 weeks ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $1201 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $1201 price target.
-
3 weeks ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $1201 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $1201 price target.
-
3 weeks ago benzinga.com
BTIG Maintains Buy on Praxis Precision Medicine, Raises Price Target to $826
BTIG analyst Kambiz Yazdi maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $810 to $826.
3 weeks ago benzinga.com
Praxis Precision Medicine Q2 2026 Earnings Call Transcript
Praxis Precision Medicine (NASDAQ:PRAX) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. Benzinga APIs provide real-time access…
1 month ago globenewswire.com
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company,…
1 month ago defenseworld.net
Reviewing Praxis Precision Medicines (NASDAQ:PRAX) & Actinium Pharmaceuticals (NYSE:ATNM)
Praxis Precision Medicines (NASDAQ: PRAX - Get Free Report) and Actinium Pharmaceuticals (NYSE: ATNM - Get Free Report) are both healthcare companies, but which is the superior business? We will…
-
1 month ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $1201 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $1201 price target.
-
1 month ago benzinga.com
Needham Reiterates Buy on Praxis Precision Medicine, Maintains $582 Price Target
Needham analyst Ami Fadia reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $582 price target.
1 month ago defenseworld.net
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Average Recommendation of “Moderate Buy” by Brokerages
Shares of Praxis Precision Medicines, Inc. (NASDAQ: PRAX - Get Free Report) have earned an average rating of "Moderate Buy" from the twenty ratings firms that are covering the stock, MarketBeat…
1 month ago seekingalpha.com
Praxis Precision Medicines: Still Potential Upside After Huge Rally (Rating Upgrade)
Praxis Precision Medicines has surged over 1,000% since April 2025, driven by pivotal clinical wins for ulixacaltamide and relutrigine. Ulixacaltamide and relutrigine, both with 2026–2027 PDUFA…
1 month ago globenewswire.com
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company,…
2 months ago defenseworld.net
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Rating of “Buy” from Brokerages
Shares of Praxis Precision Medicines, Inc. (NASDAQ: PRAX - Get Free Report) have been assigned a consensus rating of "Buy" from the twenty-two analysts that are currently covering the company,…
-
2 months ago benzinga.com
Goldman Sachs Maintains Buy on Praxis Precision Medicine, Raises Price Target to $575
Goldman Sachs analyst Kevin Strang maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $470 to $575.
2 months ago defenseworld.net
Praxis Precision Medicines (NASDAQ:PRAX) Hits New 1-Year High – What’s Next?
Praxis Precision Medicines, Inc. (NASDAQ: PRAX - Get Free Report) shares reached a new 52-week high during mid-day trading on Tuesday. The company traded as high as $391.64 and last traded at…
2 months ago defenseworld.net
9,840 Shares in Praxis Precision Medicines, Inc. $PRAX Purchased by Handelsbanken Fonder AB
Handelsbanken Fonder AB acquired a new stake in Praxis Precision Medicines, Inc. (NASDAQ: PRAX) during the second quarter, according to its most recent Form 13F filing with the Securities and…
2 months ago zacks.com
4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year
Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face major 2026 catalysts, from FDA decisions to late-stage readouts.
2 months ago seekingalpha.com
Praxis: Commercial Launch Could Smash Expectations (Video)
Prax is analyzed using a sum-of-parts valuation approach, focusing on its lead asset, Ulixa. Recent updates from the Goldman Sachs presentation highlight key developments ahead of Ulixa's commercial…
-
2 months ago benzinga.com
RBC Capital Maintains Outperform on Praxis Precision Medicine, Raises Price Target to $462
RBC Capital analyst Leonid Timashev maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and raises the price target from $449 to $462.
-
2 months ago benzinga.com
Wells Fargo Maintains Equal-Weight on Praxis Precision Medicine, Raises Price Target to $362
Wells Fargo analyst Benjamin Burnett maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Equal-Weight and raises the price target from $323 to $362.
2 months ago seekingalpha.com
Praxis Precision Medicines, Inc. (PRAX) Q2 2026 Earnings Call Transcript
Praxis Precision Medicines, Inc. (PRAX) Q2 2026 Earnings Call Transcript
2 months ago marketbeat.com
Praxis Precision Medicines Q2 Earnings Call Highlights
Praxis Precision Medicines NASDAQ: PRAX said it is preparing for potential commercial launches of ulixacaltamide for essential tremor and relutrigine for SCN2A- and SCN8A-related developmental and…
-
2 months ago benzinga.com
Needham Maintains Buy on Praxis Precision Medicine, Raises Price Target to $582
Needham analyst Ami Fadia maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $575 to $582.
2 months ago benzinga.com
Motorola Solutions Posts Upbeat Q2 Earnings, Joins Insmed, Diodes, Parker-Hannifin And Other Big Stocks Moving Higher On Thursday
US stocks mixed on Thurs. Dow Jones down 50 pts. Motorola Solutions Inc shares up 9.5% after reporting strong Q2 results & raised guidance.
-
2 months ago benzinga.com
Praxis Precision Medicine Q2 EPS $(2.87) Beats $(3.65) Estimate
Praxis Precision Medicine (NASDAQ:PRAX) reported quarterly losses of $(2.87) per share which beat the analyst consensus estimate of $(3.65) by 21.37 percent. This is a 13.29 percent increase over…
2 months ago globenewswire.com
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company,…
3 months ago globenewswire.com
Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
BOSTON, July 30, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company,…
-
3 months ago benzinga.com
BTIG Reiterates Buy on Praxis Precision Medicine, Maintains $810 Price Target
BTIG analyst Kambiz Yazdi reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $810 price target.
3 months ago defenseworld.net
Bank of New York Mellon Corp Boosts Stock Position in Praxis Precision Medicines, Inc. $PRAX
Bank of New York Mellon Corp raised its holdings in Praxis Precision Medicines, Inc. (NASDAQ: PRAX) by 11.7% during the first quarter, according to the company in its most recent Form 13F filing with…
3 months ago defenseworld.net
Fifth Third Bancorp Acquires New Holdings in Praxis Precision Medicines, Inc. $PRAX
Fifth Third Bancorp bought a new stake in Praxis Precision Medicines, Inc. (NASDAQ: PRAX) during the first quarter, according to the company in its most recent 13F filing with the Securities and…
3 months ago seekingalpha.com
Praxis Precision Medicines: Priced For Half Of What I Think It's Worth
Praxis Precision Medicines: Priced For Half Of What I Think It's Worth
-
3 months ago benzinga.com
Goldman Sachs Initiates Coverage On Praxis Precision Medicine with Buy Rating, Announces Price Target of $447
Goldman Sachs analyst Kevin Strang initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX) with a Buy rating and announces Price Target of $447.
-
3 months ago benzinga.com
Praxis Precision Medicines And Remagine Labs Announce Research Collaboration And License Agreement To Develop Iontophoretic Transdermal Patch For Delivery Of Ulixacaltamide For Essential Tremor
Collaboration aims to quickly enable ulixacaltamide to be delivered via active transdermal route Potential to expand the addressable market for ulixacaltamide beyond the initial patient population…
3 months ago globenewswire.com
Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor
Collaboration aims to quickly enable ulixacaltamide to be delivered via active transdermal route Potential to expand the addressable market for ulixacaltamide beyond the initial patient population…
4 months ago globenewswire.com
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company,…
-
4 months ago benzinga.com
Praxis Precision Medicines Announces FDA Extends PDUFA Date To December 27, 2026 For Relutrigine Following Major Amendment Submission; No New Clinical Or Safety Concerns Cited
FDA sets updated PDUFA date of December 27, 2026BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS)…
4 months ago benzinga.com
Applied Materials To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts upgraded and downgraded several top companies, including Applied Materials, Robinhood, Liquidia, Airbnb, Praxis, Alnylam, and Uniqure.
-
4 months ago benzinga.com
Needham Maintains Buy on Praxis Precision Medicine, Raises Price Target to $575
Needham analyst Ami Fadia maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $537 to $575.
4 months ago benzinga.com
Praxis' Seizure Drug Move Towards Faster Development After Positive Trial Results
FDA grants Breakthrough Therapy Designation to Praxis' elsunersen after strong seizure reduction data in SCN2A-DEE.
-
4 months ago benzinga.com
Praxis Precision Medicines Receives Breakthrough Therapy Designation From FDA For Elsunersen To Treat Seizures Associated With SCN2A Development And Epileptic Encephalopathy
Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that the U.S. Food and Drug…
-
4 months ago benzinga.com
RBC Capital Initiates Coverage On Praxis Precision Medicine with Outperform Rating, Announces Price Target of $449
RBC Capital analyst Leonid Timashev initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform rating and announces Price Target of $449.
-
5 months ago benzinga.com
Oppenheimer Maintains Outperform on Praxis Precision Medicine, Lowers Price Target to $650
Oppenheimer analyst Jay Olson maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and lowers the price target from $750 to $650.
-
5 months ago benzinga.com
Truist Securities Maintains Buy on Praxis Precision Medicine, Lowers Price Target to $616
Truist Securities analyst Danielle Brill maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and lowers the price target from $715 to $616.
-
5 months ago benzinga.com
Deutsche Bank Maintains Buy on Praxis Precision Medicine, Lowers Price Target to $374
Deutsche Bank analyst David Hoang maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and lowers the price target from $420 to $374.
-
5 months ago benzinga.com
Wedbush Maintains Underperform on Praxis Precision Medicine, Lowers Price Target to $162
Wedbush analyst Laura Chico maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Underperform and lowers the price target from $166 to $162.
5 months ago benzinga.com
CrowdStrike To Gain 7%? Here Are 10 Top Analyst Forecasts For Tuesday
Wall Street analysts change ratings for top stocks: CRWD price target raised, FULC target lowered, HPQ target raised, PRAX target cut, GNSS target raised, INTU target lowered, GH target raised, CRDO…
-
5 months ago benzinga.com
Baird Maintains Outperform on Praxis Precision Medicine, Lowers Price Target to $400
Baird analyst Joel Beatty maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and lowers the price target from $433 to $400.
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
5 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Praxis Precision Medicine, Lowers Price Target to $1201
HC Wainwright & Co. analyst Douglas Tsao maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and lowers the price target from $1245 to $1201.